

Amoxibactin 250 mg tablets for dogs

Authorised

- Amoxicillin trihydrate

Product identification

Medicine name:

Amoxibactin 250 mg tablets for dogs
Amoxibactin 250 mg tablets for dogs

Active substance:

Amoxicillin trihydrate

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Amoxicillin trihydrate
287.50 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CA04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Ireland

Package description:

Cardboard box of 9 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 8 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 7 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 6 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 3 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 25 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 2 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 10 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 1 Aluminium - PVC/PE/PVDC blister of 10 tablets.

Cardboard box of 50 Aluminium - PVC/PE/PVDC blisters of 10 tablets

Cardboard box of 5 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box of 4 Aluminium - PVC/PE/PVDC blisters of 10 tablets.

Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Le Vet. Beheer B.V.

Marketing authorisation date:

16/01/2015

Manufacturing sites for batch release:

Lelypharma B.V.

Responsible authority:

Health Products Regulatory Authority

Authorisation number:

VPA10475/013/002

Date of authorisation status change:

16/01/2015

Reference member state:

Netherlands

Procedure number:

NL/V/0186/002

Concerned member states:

Austria Belgium Cyprus Czechia Denmark Estonia Finland France Germany
Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway
Poland Portugal Romania Slovakia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to

www.adrreports.eu/vet